Assignee
ACLARIS THERAPEUTICS INC
US·22 granted patents·15 pending applications·51 citations·filing 2015–2025
Top patents by PatentIndex Score
37 records- 0196US10981906B2Substituted pyrrolopyridine JAK inhibitors and methods of making and using the sameACLARIS THERAPEUTICS INC·Filed 2018·Granted Apr 20, 2021·9 cites·21 claims
- 0294US11739086B2Substituted pyrrolopyridine JAK inhibitors and methods of making and using the sameACLARIS THERAPEUTICS INC·Filed 2021·Granted Aug 29, 2023·4 cites·5 claims
- 0394US10800775B2Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the sameACLARIS THERAPEUTICS INC·Filed 2018·Granted Oct 13, 2020·8 cites·20 claims
- 0492US11820775B2Pyrrolopyrimidine ITK inhibitorsACLARIS THERAPEUTICS INC·Filed 2021·Granted Nov 21, 2023·2 cites·34 claims
- 0590US12281111B2Substituted pyrrolopyridine JAK inhibitors and methods of making and using the sameACLARIS THERAPEUTICS INC·Filed 2023·Granted Apr 22, 2025·1 cites·7 claims
- 0690US10729720B2Peroxide formulations and methods and applicators for using the sameACLARIS THERAPEUTICS INC·Filed 2018·Granted Aug 4, 2020·1 cites·36 claims
- 0789US11767309B2Methods of synthesizing substituted pyridinone-pyridinyl compoundsACLARIS THERAPEUTICS INC·Filed 2021·Granted Sep 26, 2023·1 cites·36 claims
- 0889US10098910B2Peroxide formulations and methods and applicators for using the sameACLARIS THERAPEUTICS INC·Filed 2016·Granted Oct 16, 2018·6 cites·18 claims
- 0988US11844801B2Oral compositions of MK2 pathway inhibitor for treatment of immune conditionsACLARIS THERAPEUTICS INC·Filed 2021·Granted Dec 19, 2023·2 cites·64 claims
- 1088US10335391B2Stabilized oxymetazoline formulations and their usesACLARIS THERAPEUTICS INC·Filed 2018·Granted Jul 2, 2019·4 cites·37 claims
- 1188US9980983B2Peroxide formulations and methods and applicators for using the sameACLARIS THERAPEUTICS INC·Filed 2017·Granted May 29, 2018·5 cites·25 claims
- 1287US9675639B2Peroxide formulations and methods and applicators for using the sameACLARIS THERAPEUTICS INC·Filed 2015·Granted Jun 13, 2017·5 cites·70 claims
- 1385US12297203B2Pyrrolopyrimidine ITK inhibitorsACLARIS THERAPEUTICS INC·Filed 2023·Granted May 13, 2025·0 cites·5 claims
- 1482US11021482B2Pyrrolopyrimidine ITK inhibitorsACLARIS THERAPEUTICS INC·Filed 2019·Granted Jun 1, 2021·2 cites·21 claims
- 1580US12384757B2Methods of synthesizing substituted pyridinone-pyridinyl compoundsACLARIS THERAPEUTICS INC·Filed 2023·Granted Aug 12, 2025·0 cites·10 claims
- 1680US12370195B2Oral compositions of MK2 pathway inhibitor for treatment of immune conditionsACLARIS THERAPEUTICS INC·Filed 2023·Granted Jul 29, 2025·0 cites·24 claims
- 1778US10493103B2Peroxide formulations and methods and applicators for using the sameACLARIS THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·1 cites·21 claims
- 1877US2026035373A1Pyrrolopyrimidine itk inhibitorsACLARIS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1976US2026062410A1Substituted pyrrolopyridine jak inhibitors and methods of making and using the sameACLARIS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2076US2025387393A1Oral compositions of mk2 pathway inhibitor for treatment of immune conditionsACLARIS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2172US2020016153A1Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonistsACLARIS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2270US2021137974A1Peroxide formulations and methods and applicators for using the sameACLARIS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2367US10653721B2Peroxide formulations and methods and applicators for using the sameACLARIS THERAPEUTICS INC·Filed 2017·Granted May 19, 2020·0 cites·27 claims
- 2466US2022372034A1Substituted pyrrolopyridines as jak inhibitorsACLARIS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2563US2023286950A1Methods of synthesizing deuterated substituted pyridinone-pyridinyl compoundsACLARIS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2661US2019167566A1Pharmaceutical cream compositions of oxymetazoline and methods of useACLARIS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2759US2019352300A1Pyrrolopyrimidine itk inhibitors for treating inflammation and cancerACLARIS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2858US10316038B2Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancerACLARIS THERAPEUTICS INC·Filed 2018·Granted Jun 11, 2019·0 cites·27 claims
- 2957US12403141B2Deuterated MK2 pathway inhibitors and methods of using the sameACLARIS THERAPEUTICS INC·Filed 2020·Granted Sep 2, 2025·0 cites·7 claims
- 3057US11420966B2Substituted pyrrolopyridines as JAK inhibitorsACLARIS THERAPEUTICS INC·Filed 2020·Granted Aug 23, 2022·0 cites·17 claims
- 3157US2019106439A1Heterocyclic itk inhibitors for treating inflammation and cancerACLARIS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3256US2023365555A1Crystalline polymorph form a of a jak inhibitorand methods for its preparationACLARIS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3354US10150783B2Heterocyclic ITK inhibitors for treating inflammation and cancerACLARIS THERAPEUTICS INC·Filed 2017·Granted Dec 11, 2018·0 cites·21 claims
- 3453US2024139170A1Topical formulations of a jak 1/3 inhibitor and methods of use thereof for treatment of atopic dermatitis and other skin conditionsACLARIS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3551US2022235043A1Substituted sulfonamide pyrrolopyridines as jak inhibitorsACLARIS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3649US2019060311A1Compositions and methods for treatment of vitiligoACLARIS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3740US2018050009A1Methods and compositions for the treatment of wartsACLARIS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →